Skip to content

Immunome

US · IMNM #2671 by market cap Listed 2020
15.69 -0.92 -5.54%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 16.31 -1.81%
After-hours 15.69 0.00%
29.8315.6915.692026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on IMNM?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -27.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has fallen to 13.7% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days D → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C-

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability F

How much profit the business keeps from each dollar of sales and capital.

Operating margin -3,228.8% Better than 2%
Net margin -3,060.0% Better than 2%
Return on equity -52.1% Better than 9%
Return on invested capital -54.4% Better than 5%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -45.0% Better than 8%
6-month return -27.6% Better than 20%
12-month return (ex latest month) -2.9% Better than 31%
Distance below 52-week high 47.8% Better than 21%
Financial Health A-

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.7x Better than 96%
Debt to assets 0.6% Better than 96%
Interest coverage -2,470.1x Better than 1%
Analyst View A

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 90.0% Better than 73%
Upside to average target 121.8% Better than 87%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -16.41%
1M -12.44%
3M -44.12%
6M -27.12%
YTD -26.96%
1Y -10.39%
3Y +101.41%
5Y -8.78%

Key statistics

Price & volume

Prev close
16.61
Open
16.45
Day range
15.55 - 16.73
Avg price
15.90
Volume
1.06M
Turnover
16.79M
Amplitude
7.10%
52-week range
15.55 - 30.06

Valuation

P/E
-6.46
P/E (TTM)
-5.97
P/B
4.08
EPS
-2.43
Net profit
-286.92M
Net assets
454.34M

Share structure

Market cap
1.85B
Float cap
1.78B
Shares out
118.07M
Float shares
113.15M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2020-10-02
52-week range 1% of range
15.55 30.06

47.8% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+7.30M net over the window

Short interest

Shares short
16.17M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Immunome (IMNM)?

Immunome last traded at 15.69. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Immunome's market cap?

About 1.85B.

What is the P/E ratio of Immunome?

The trailing twelve-month P/E is -5.97. The Valuation tab shows it against the stock's own five-year range.

Does Immunome pay a dividend?

Immunome does not currently pay a regular dividend.

Is Immunome a buy according to analysts?

The consensus of 10 analysts is a Buy rating, with an average 12-month price target of 34.80, which implies 121.8% upside from the current price. This is not investment advice.

What is Immunome's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Immunome a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Immunome discussion 0 comments

Add a comment